Qualification of National Cancer Institute-Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials

被引:16
|
作者
Scheuermann, Joshua S. [1 ]
Reddin, Janet S. [1 ]
Opanowski, Adam [2 ]
Kinahan, Paul E. [3 ]
Siegel, Barry A. [4 ,5 ]
Shankar, Lalitha K. [6 ]
Karp, Joel S. [1 ]
机构
[1] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
[2] Amer Coll Radiol Imaging Network, Philadelphia, PA USA
[3] Univ Washington, Dept Radiol, Seattle, WA 98195 USA
[4] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA
[5] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA
[6] NCI, Canc Imaging Program, Rockville, MD USA
关键词
CQIE; PET qualification; quantitative imaging; STANDARDIZED UPTAKE VALUE; F-18-FDG PET/CT; MULTICENTER TRIALS; FDG-PET/CT; NETWORK; EXPERIENCE; BIOMARKER; VARIANCE; PROTOCOL; THERAPY;
D O I
10.2967/jnumed.116.186759
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The National Cancer Institute developed the Centers for Quantitative Imaging Excellence (CQIE) initiative in 2010 to prequalify imaging facilities at all of the National Cancer Institute-designated comprehensive and clinical cancer centers for oncology trials using advanced imaging techniques, including PET. Here we review the CQIE PET/CT scanner qualification process and results in detail. Methods: Over a period of approximately 5 y, sites were requested to submit a variety of phantoms, including uniform and American College of Radiology-approved phantoms, PET/CT images, and examples of clinical images. Submissions were divided into 3 distinct time periods: initial submission (T0) and 2 requalification submissions (T1 and T2). Images were analyzed using standardized procedures, and scanners received a pass or fail designation. Sites had the opportunity to submit new data for scanners that failed. Quantitative results were compared across scanners within a given time period and across time periods for a given scanner. Results: Data from 65 unique PET/CT scanners across 56 sites were submitted for CQIE T0 qualification; 64 scanners passed the qualification. Data from 44 (68%) of those 65 scanners were submitted for T2. From T0 to T2, the percentage of scanners passing the CQIE qualification on the first attempt rose from 38% for T1 to 67% for T2. The most common reasons for failure were SUV outside specifications, incomplete submission, and uniformity issues. Uniform phantom and American College of Radiology-approved phantom results between scanner manufacturers were similar. Conclusion: The results of the CQIE process showed that periodic requalification may decrease the frequency of deficient data submissions. The CQIE project also highlighted the concern within imaging facilities about the burden of maintaining different qualifications and accreditations. Finally, for quantitative imaging-based trials, further evaluation of the relationships between the level of the qualification (e.g., bias or precision) and the quality of the image data, accrual rates, and study power is needed.
引用
收藏
页码:1065 / 1071
页数:7
相关论文
共 50 条
  • [11] Compliance With Price Transparency Rules at US National Cancer Institute-Designated Cancer Centers
    Chino, Fumiko
    Johnson, Jordan
    Moss, Haley
    JAMA ONCOLOGY, 2021, 7 (12) : 1903 - 1904
  • [12] Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute-Designated Cancer Centers
    Prindiville, Sheila A.
    Sarosy, Gisele A.
    Loose, David
    Ciolino, Henry
    Doroshow, James H.
    CANCER JOURNAL, 2022, 28 (02): : 111 - 117
  • [13] Five National Cancer Institute-Designated Cancer Centers' Data Collection on Racial/Ethnic Minority Participation in Therapeutic Trials
    Hawk, Ernest T.
    Habermann, Elizabeth B.
    Ford, Jean G.
    Wenzel, Jennifer A.
    Brahmer, Julie R.
    Chen, Moon S., Jr.
    Jones, Lovell A.
    Hurd, Thelma C.
    Rogers, Lisa M.
    Nguyen, Lynne H.
    Ahluwalia, Jasjit S.
    Fouad, Mona
    Vickers, Selwyn M.
    CANCER, 2014, 120 : 1113 - 1121
  • [14] The Prevalence of Dissemination and Implementation Research and Training Grants at National Cancer Institute-Designated Cancer Centers
    Mueller, Nora M.
    Hsieh, Ada
    Ramanadhan, Shoba
    Lee, Rebekka M.
    Emmons, Karen M.
    JNCI CANCER SPECTRUM, 2022, 6 (01)
  • [15] Evolution of community outreach and engagement at National Cancer Institute-Designated Cancer Centers, an evolving journey
    Pohl, Sarah A.
    Nelson, Barry A.
    Patwary, Tanjeena R.
    Amanuel, Salina
    Benz, Edward J.
    Lathan, Christopher S.
    CA-A CANCER JOURNAL FOR CLINICIANS, 2024, 74 (04) : 383 - 396
  • [16] Tracking community outreach and engagement activities among National Cancer Institute-designated cancer centers
    Burus, Todd
    Mcafee, Caree R.
    Hull, Pamela C.
    Leader, Amy E.
    Mcnair, Christopher
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 117 (02): : 335 - 337
  • [17] Improved Survival in Cervical Cancer Patients Receiving Care at National Cancer Institute-Designated Cancer Centers
    McDaniels-Davidson, Corinne
    Feng, Christine H.
    Martinez, Maria Elena
    Canchola, Alison J.
    Gomez, Scarlett Lin
    Nodora, Jesse N.
    Patel, Sandip P.
    Mundt, Arno J.
    Mayadev, Jyoti S.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2023, 78 (01) : 27 - 28
  • [18] PATTERN OF BEVACIZUMAB USE IN PATIENTS WITH GLIOBLASTOMA AT NATIONAL CANCER INSTITUTE-DESIGNATED CANCER CENTERS IN 2017
    Ranjan, Surabhi
    Skorupan, Nebojsa
    Ye, Xiaobu
    Yankulina, Olga
    Grossman, Stuart A.
    Holdhoff, Matthias
    NEURO-ONCOLOGY, 2017, 19 : 110 - 110
  • [19] Compliance of National Cancer Institute-Designated Cancer Centers With January 2021 Price Transparency Requirements
    Childers, Christopher P.
    Guorgui, Jacob
    Siddiqui, Sami
    Donahue, Timothy
    JAMA SURGERY, 2022, 157 (10) : 959 - 960
  • [20] Racial, Ethnic, and Gender Representation in Leadership Positions at National Cancer Institute-Designated Cancer Centers
    Morgan, Austin
    Shah, Kanan
    Tran, Kevin
    Chino, Fumiko
    JAMA NETWORK OPEN, 2021, 4 (06) : E2112807